PHASE I PHARMACOKINETIC STUDY OF CARBOPLATIN IN COMBO WITH WEEKLY PACLITAXEL

卡铂联合每周紫杉醇的 I 期药代动力学研究

• 批准号: 6304699
• 负责人: CHANDRA BELANI
• 金额: $ 0.3万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6304699
• 关键词: carboplatin; clinical research; clinical trial phase I; combination chemotherapy; drug administration rate /duration; drug adverse effect; drug interactions; drug screening /evaluation; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; paclitaxel; pharmacokinetics

Phase I of the study calls for a combination of carboplatin given every three weeks with weekly paclitaxel. The dose intensity of paclitaxel can be increased considerably by weekly administration with minimal hematological toxicity and in addition, paclitaxel may also have a protective effect on carboplatin induced thrombocytopenia. It is anticpated that the increased dose intensity of paclitaxel in this combination would result in developing an active regimen without added toxicity as seen on a regular every three-week schedule.

该研究的第一阶段要求每三周给予卡铂与每周给予紫杉醇的组合。每周给药可显着增加紫杉醇的剂量强度，且血液学毒性最小，此外，紫杉醇还可能对卡铂引起的血小板减少症具有保护作用。预计该组合中紫杉醇剂量强度的增加将导致开发出一种积极的治疗方案，而不会增加如每三周定期方案中所见的毒性。